- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03204799
Metagenomic Analysis of Human Gut Microbiota in Patients With Metabolic Diseases Including Diabetes
Metagenomic Analysis of Human Gut Microbiota in Patients With Metabolic Diseases Including Diabetes.
Microbiota is important for immunology, hormonal and metabolic homeostasis in human and could influence on developing diabetes and obesity. Recent studies investigates microbiota by metagenomic sequencing, however, the composite of microbiota and its metabolic role has not been fully determined. Metagenomics and microbiome analysis could early diagnose metabolic disorders and suggest treatment options for metabolic diseases.
In this study, the investigators investigate the composite of microbiota and deduct basic information for treatment models using metagenomic sequencing.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
- Cross-section study: normal/prediabetes/drug naïve type2 diabetes: compare microbiota using metagenomic sequencing among three groups.
- Observational prospective study: metformin/sodium glucose co-transporter 2 (SGLT2) inhibitor/ezetimibe: compare microbiota using metagenomic sequencing before and after drug treatment.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of, 03722
- Recruiting
- Yonsei University College of Medicine, Department of internal Medicine, Division of Endocrinology, Severance Hospital, Diabetes Center
-
Contact:
- Yong-ho Lee, M.D., Ph.D.
- Phone Number: 82-2-2228-1943
- Email: yholee@yuhs.ac
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- normal group: body mass index [BMI]<23kg/m2, without diabetes mellitus history
- prediabetes group: fasting blood glucose ≥100 mg/dL and <126 mg/dL or postprandial blood glucose ≥140 mg/dL and <200 mg/dL
- type 2 diabetes according to ADA(American Diabetes Association) guideline (1) fasting blood glucose ≥126 mg/dL, (2) random blood glucose ≥200 mg/dL and with typical diabetes symptoms, (3) glycated hemoglobin A1c ≥6.5% and anti-hypoglycemic drug naive
- patients with type 2 diabetes, metformin monotherapy, SGLT2 inhibitor monotherapy
- patients with dyslipidemia, ezetimibe therapy
Exclusion Criteria:
- inflammatory bowel disease (Crohn's disease, ulcerative colitis)
- history of stomach, small intestine or colon resection operation
- on antibiotics therapy
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
normal group
normal group (without diabetes diagnosis/treatment and in normoglycemia
|
newly diagnosed type 2 diabetes patients who start to metformin monotherapy
newly diagnosed dyslipidemia patients who start to ezetimibe therapy
|
prediabetes
high risk, impaired fasting glucose, impaired glucose tolerance
|
newly diagnosed type 2 diabetes patients who start to metformin monotherapy
newly diagnosed dyslipidemia patients who start to ezetimibe therapy
|
drug naive type 2 diabetes
type 2 diabetes, anti-hypoglycemic drug naive
|
newly diagnosed type 2 diabetes patients who start to metformin monotherapy
newly diagnosed dyslipidemia patients who start to ezetimibe therapy
|
type 2 diabetes with metformin monotherapy
|
newly diagnosed type 2 diabetes patients who start to metformin monotherapy
|
type 2 diabetes with SGLT2 inhibitor monotherapy
|
newly diagnosed type 2 diabetes patients who start to SGLT2 inhibitor monotherapy
|
dyslipidemia with ezetimibe therapy
|
newly diagnosed dyslipidemia patients who start to ezetimibe therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Metagenomic profile change
Time Frame: 10 days (acute effect)
|
Stool metagenomic profile change in acute and chronic phase
|
10 days (acute effect)
|
Metagenomic profile change
Time Frame: 3 months (chronic effect)
|
Stool metagenomic profile change in acute and chronic phase
|
3 months (chronic effect)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
blood glucose change
Time Frame: 3 months
|
fasting blood glucose
|
3 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Endocrine System Diseases
- Lipid Metabolism Disorders
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Dyslipidemias
- Metabolic Diseases
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Metformin
- Sodium-Glucose Transporter 2 Inhibitors
- Ezetimibe
Other Study ID Numbers
- 4-2016-0950
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
Diabetes Foundation, IndiaNational Diabetes Obesity and Cholesterol FoundationRecruitingType 2 Diabetes Mellitus With ComplicationIndia
Clinical Trials on Metformin
-
Anji PharmaSuspendedDiabetes Mellitus, Type 2Spain, United States, Canada, Hungary, Brazil, Czechia, Poland, Bulgaria
-
NuSirt BiopharmaCompletedType 2 Diabetes MellitusUnited States
-
ShionogiCompleted
-
Bristol-Myers SquibbCompletedType 2 Diabetes MellitusSouth Africa, United States, Canada, Puerto Rico, Hungary, Germany, Czechia, Poland, Romania, United Kingdom
-
Charles University, Czech RepublicCompleted
-
Hoffmann-La RocheCompletedDiabetes Mellitus Type 2United States, Mexico, Argentina
-
Hadassah Medical OrganizationWithdrawn
-
Woman'sPfizer; American Cancer Society, Inc.; Our Lady of the Lake Regional Medical...WithdrawnInsulin Resistance | Breast Cancer Stage | Racial BiasUnited States
-
Garvan Institute of Medical ResearchWeizmann Institute of ScienceActive, not recruitingType 2 Diabetes Mellitus | Pre DiabetesAustralia
-
University Hospital, Basel, SwitzerlandCompletedBecker's Muscular Dystrophy (BMD)Switzerland